Interactions between corticosteroids and β agonists

Thorax

Volumn 55, Issue 7, 2000, Pages 595-602

  Taylor, D R ^a   Hancox, R J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; FENOTEROL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; SALBUTAMOL; TERBUTALINE;

ASTHMA; BRONCHUS REACTIVITY; DOWN REGULATION; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ACUTE DISEASE; ADRENERGIC BETA-AGONISTS; ASTHMA; DRUG INTERACTIONS; GLUCOCORTICOIDS; HUMANS; RECEPTORS, GLUCOCORTICOID;

EID: 0034044766     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.55.7.595     Document Type: Review

References (98)

1. 1 British Thoracic Society. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997;52(Suppl 1):S1-21.
2. 2 Sears MR. Epidemiology of asthma. In: Barnes PJ, Rodger IWB, Thomson NC, eds. Asthma: basic mechanisms and clinical management. 3rd ed. San Diego: Academic Press, 1998: 1-33.
3. 3 Davies AO, DeLean A, Lefkowitz RJ. Myocardial beta-adrenergic receptors from adrenalectomised rats: impaired formation of high-affinity agonist-receptor complexes. Endocrinology 1981;108:720-2.
4. 4 Davies AO, Lefkowtiz RJ. Regulation of beta-adrenergic receptors by steroid hormones. Ann Rev Physiol 1984;46: 119-30.
5. 5 Torphy TJ. Beta-receptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends Pharmacol Sci 1994;15:370-4.
6. 6 Hausdorf WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitisation of beta-adrenergic receptor function. EASEB J 1990;4:2881-9.
7. 7 McGraw DW, Liggett SB. Heterogeneity of the β-adrenergic receptor kinase expression in the lung accounts for cell-specific desensitisation of the β2-adrenergic receptor. J Biol Chem 1999;272:7338-44.
8. 8 Hui KKP, Conolly ME, Tashkin DP. Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids. Clin Pharmacol Ther 1982;32:566-71.
9. 9 Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995;152:838-60.
10. 10 Kobilka BK, Dixon RAF, Frielle T, et al. cDNA for the human beta-adrenergic receptor: a protein with multiple membrane spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet derived growth factor. Proc Natl Acad Sci USA 1987;84:46-50.
11. 11 Emorine LJ, Marullo S, Delavier-Klutchko C, et al. Structure of the gene for human beta-2 adrenergic receptor: expression and promoter characterisation. Proc Natl-Acad Sci USA 1987;84:6995-9.
12. 12 Hadcock JR, Malbon CC. Regulation of beta-adrenergic receptors by permissive hormones: glucocorticoids increase steady state levels of receptor mRNA Proc Natl Acad Sci USA 1988;85:8415-9.
13. 13 Malbon CC, Hadcock JR. Evidence that glucocorticoid response elements in the 5′-non-coding region of the hamster beta-2 adrenergic receptor are obligate for glucocorticoid regulation of receptor mRNA levels. Biochem Biophys Res Commun 1988;154:676-81.
14. 14 Mak JCW, Nishikawa M, Barnes PJ. Glucocorticoids increase beta-2 adrenergic receptor transcription in human lung. Am J Physiol 1995;268:L41-6.
15. 15 Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on down-regulation of pulmonary beta-2 adrenergic receptors in vivo. J Clin Invest 1995; 96:99-106.
16. 16 Scarceriaux V, Pelaprat D, Forgez P, et al. Effects of dexamethasone and forskolin on neurotensin production in rat hypothalamic cultures. Endocrinology 1995;136:2554-60.
17. 17 Dong Y, Aronsson M, Gustafsson JA, et al. The mechanism of cAMP-induced glucocorticoid receptor expression. J Biol Chem 1989;264:13679-83.
18. 18 Adcock IM, Shirasaki H, Gelder CM, et al. The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sci 1994;55:1147-53.
19. 19 Van der Saag PT, Caldenhoven E, Van der Stolpe A. Molecular mechanisms of steroid action: a novel type of crosstalk between glucocorticoids and NF-kappa B transcription factors. Eur Respir J 1996;9(Suppl 22):146-52s.
20. 20 Janknecht R, Hunter T. A growing co-activator network. Nature 1996;383:22-3.
21. 21 Peters MJ, Adcock IM, Brown CR, et al. Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. Eur J Pharmacol 1995;289:275-81.
22. 22 Peters MJ, Adcock IM, Brown CR, et al. Beta-agonist inhibition of steroid-receptor DNA binding activity in human lung. Am Rev Respir Dis 1993;147:A772.
23. 23 Stevens DA, Barnes PJ, Adcock IM. Beta-agonists inhibit DNA binding of glucocorticoid responses in human pulmonary and bronchial epithelial cells. Am J Respir Crit Care Med 1995;151:A195.
24. 24 Hancox RJ, Stevens DA, Adcock IM, et al. Effects of inhaled beta-agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax 1999;54:488-92.
25. 25 Korn SH, Wouters EFM, Wesseling G, et al. Interaction between glucocorticoids and beta-2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells Biochem Pharmacol 1998;56: 1561-9.
26. 26 Eickelberg O, Roth M, Lorx R, et al. Ugand-binding activation of the glucocorticoid receptor by beta-2 adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-10.
27. 27 Oddera S, Silvestri M, Testi R, et al. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. Respiration 1998;65:199-204.
28. 28 Anenden V, Egemba G, Kessel B, et al. Salmeterol faciliatanon of fluticasone-induced apoptosis in eosinophils of asthmatics pre-and post-antigen challenge. Eur Respir J 1998;12:157s.
29. 29 Pang L, Knox AJ. Synergistic inhibition by β agonists and corticosteroids on TNFμ induced IL-8 release from cultured human airway smooth muscle cells. Am J Respir Cell Mol Biol 2000 (in press).
30. 30 Seldon PM, Stevens, Adcock IM, et al. Albuterol does not antagonize the inhibitory effect of dexamethasone on monocyte cytokine release. Am J Respir Crit Care Med 1998;157:803-9.
31. 31 Nielson CP, Hadjokas NE. Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med 1998;157:184-91.
32. 32 Geddes BA, Jones TR, Dvorsky RJ, et al. Interaction of glucocorticoids and bronchodilators on isolated guinea-pig tracheal and human bronchial smooth muscle. Am Rev Respir Dis 1974;110:420-7.
33. 33 Stephan WC, Chick TW, Avner BP, et al. Tachyphylaxis to inhaled isoproterenol and the effect of methylprednisolone in dogs. J Allergy Clin Immunol 1980;65:105-9.
34. 34 Ellul-Micallef R, Fenech FF. Effect of intravenous prednisolone in asthmatics with dimished adrenergic responsiveness. Lancet 1975;ii:1269-71.
35. 35 Pansegrouw DF, Weich DJV, LeRoux FPJ. Beta-adrenergic receptor tachyphylaxis in acute severe asthma. S Afr Med J 1991;80:229-30.
36. 36 Tan KS, Grove A, McLean A, et al. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997;156:28-35.
37. 37 Arnaud A, Charpin J. Interaction between corticosteroids and beta-2 agonists in acute asthma. Eur J Respir Dis Suppl 1982;122:126-31.
38. 38 Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med 1998;157:698-703.
39. 30 Pearce N, Crane J, Burgess C, et al. Beta-agonists and asthma mortality: deja vu. Clin Exp Allergy 1991;21:401-10.
40. 40 McDevitt DG, Shanks RG, Swanton JG. Further observations on the cardiotoxicity of isoprenaline during hypoxia. Br J Pharmacol 1974;50:335-44.
41. 11 Guideri G, Barletta M, Lehr D. Extraordinary potentiation of isoproterenol cardiotoxicity by corticoid pre-treatment. Cardiovasc Res 1974;8:775-86.
42. 42 Aziz I, McFarlane LC, Lipworth BJ. Concomitant inhaled corticosteroid resensitises cardiac beta-2 adrenoceptors in the presence of long-acting beta-2 agonist therapy. Eur J Clin Pharmacol 1998;54:377-81.
43. 43 Lin RY, Newman TG, Sauter D, et al. Association between reported use of inhaled triamcinolone and differential short-term responses to aerosolised albuterol in an emergency department setting. Chest 1994;106:452-7.
44. 44 Taylor DR, Wilkins GT, Herbison GP, et al. Interaction between corticosteroid and beta-agonist drugs: biochemical and cardiovascular effects in normal subjects. Chest 1995;102:519-24.
45. 45 Molfino NA, Nannini LJ, Martelli AN, et al. Respiratory arrest in near-fatal asthma. N Engl J Med 1991;324:285-8.
46. 40 Harrison AR, Richards R, Howarth P, et al. Interaction of inhaled corticosteroids and beta-2 agonists in asthmatic subjects. Thorax 1984;39:710-1.
47. 47 Molema J, Lammers J-WJ, Van Herwaarden CLA, et al. Effects of inhaled beclomethasone dipropionate on beta-2 receptor function in the airways and adrenal responsiveness in bronchial asthma. Eur J Clin Pharmacol 1988;34:577-83.
48. 48 Wempe JB, Postma DS, Breederveld N, et al. Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway responsiveness in asthma. J Allergy Clin Immunol 1992;89:679-87.
49. 40 Hjemdahl P, Zetterlund A, Larsson K. Beta-2 agonist treatment reduces beta-2 sensitivity in alveolar macrophages despite corticosteroid treatment. Am J Respir Crit Care Med 1996;153:576-81.
50. 50 Hancox RJ, Aldridge RE, Cowan JA, et al. Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J 1999;14:283-7.
51. 51 Newnham DM, Grove A, McDevitt DG, et al. Subsensitivity of bronchodilator and systemic beta-2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients Thorax 1995;50:497-504.
52. 52 Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995;346:201-6.
53. 53 Kalra S, Swystun VA, Bhagat R, et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996;109: 953-6.
54. 54 Yates DH, Kharitonov SA, Barnes PJ. An inhaled corticosteroid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta-agonist. Am J Respir Crit Care Med 1996;154:1603-7.
55. 55 Booth H, Bish R, Walters J, et al. Salmeterol tachyphylaxis in steroid treated asthmatics. Thorax 1996,51:1100-4.
56. 56 Simons FER, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99:655-9.
57. 57 Giannini D, Bacci E, Dente FL, et al. Inhaled beclomethasone dipropionate reverts tolerance to the protective effects of salmeterol. Chest 1999;115:629-34.
58. 58 Tan KS, McFarlane LC, Lipworth BJ. Concomitant administration of low dose prednisolone protects against in vivo beta-2 adrenoceptor subsensitivity induced by regular formoterol. Chest 1998;113:34-41.
59. 50 Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case control study. Lancet 1989;i:917-22.
60. 60 Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990;45:170-5.
61. 61 Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-87: a further case control study. Thorax 1991;46: 105-11.
62. 62 Gauvreau GM, Jordana M, Watson RM, et al. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med 1997;156:1738-45.
63. 63 Aldridge RE, Hancox RJ, Taylor DR, et al. Effects of terbutaline and budesonide on sputum inflammatory cells. Am J Respir Crit Care Med 2000 (in press).
64. 64 Manolitsas ND, Wang J, Devalia JL, et al. Regular albuterol, nedocromil sodium and bronchial inflammation in asthma. Am J Respir Crit Care Med 1995;151:1925-30.
65. 65 Jones SA, Taylor DR. Excessive use of salbutamol: the potential benefits of dose reduction. A case report. NZ Med J 1999;112:448-50.
66. 66 Van Metre TE. Adverse effects of inhalation of excessive amounts of nebulised isoproterenol in status asthmaticus. J Allergy 1969;43:101-13.
67. 67 Reisman RE. Asthma induced by adrenergic aerosols. J Allergy 1970;46:162-7.
68. 68 Wong CS, Wahedna I, Pavord ID, et al. Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am J Respir Crit Care Med 1994,150:1260-70.
69. 60 Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled beta-2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine Am J Respir Crit Care Med 1995;152:1485-9.
70. 70 Haahtela T, Alanko K, Muittari A, et al. The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma. Ann Allergy 1989;61:63-6.
71. 71 Horn CR, Clark TJH, Cochrane GM. Can the morbidity of asthma be reduced by high dose inhaled therapy? A prospective study. Respir Med 1990;84:61-6.
72. 72 Waalkens HJ, Gerritsen J, Koeter GH, et al. Budesonide and terbutaline or terbutaline alone in children with mild asthma: effects on bronchial hyper-responsiveness and diurnal variation in peak flow. Thorax 1991;46:499-503.
73. 73 Van Essen Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months treatment with inhaled corticosteroid and or beta-2 agonists on lung function, airway responsiveness and symptoms in children with asthma. Am Rev Respir Dis 1992;146:547-54.
74. 74 Kerstjens HAM, Brand PLP, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992;327:1413-9.
75. 75 Dompeling E, Van Schayck CP, Van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator treatment by adding inhaled corticosteroids. Am Intern Med 1993;118:770-8.
76. 76 Dahl R, Pedersen B, Hagglof B. Nocturnal asthma: effect of treatment with oral sustained-release terbutaline, inhaled budesonide, and the two in combination. J Allergy Clin Immunol 1989;83:811-5.
77. 77 Bennati D, Piacentini GL, Peroni DG, et al. Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol. J Asthma 1989;26:359-64.
78. 78 Selroos O, Nyholm J-E. Influence of a budesonide-terbutaline combination on bronchial reactivity. Clin Exp Allergy 1990;20:76.
79. 70 Wilding PJ, Clark MM, Oborne J, et al. Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax 1994;51:689-92.
80. 80 Barnes PJ, O'Connor BJ. Use of a fixed combination beta-2 agonist and steroid dry powder inhaler in asthma. Am J Respir Crit Care Med 1995;151:1053-7.
81. 81 Hancox RJ, Cowan JO, Flannery EM, et al. Randomised trial of an inhaled beta-agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax 1999;54:482-7.
82. 82 Verberne AAPH, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1996;156: 688-95.
83. 83 Simons FE. A comparison of beclomethasone, salmeterol and placebo in children with asthma. N Engl J Med 1997;337:1659-65.
84. 84 Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1995; 344:219-24.
85. 85 Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
86. 86 Pearlman DS, Stricker W, Weinstein W, et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol 1999;82:257-65.
87. 87 Van Noord JA, Schreurs AJM, Mol SJM, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54:207-12.
88. 88 Weersink EJ, Douma RR, Postma DS, et al. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am J Respir Crit Care Med 1997;155:1241-6.
89. 80 Murray JJ, Church JL, Anderson WH, et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 1999;20:173-80.
90. 90 Baraniuk J, Murray JJ, Nathan RA, et al. Fluticasonc alone or in combination with salmeterol vs. triamcinolone in asthma. Chest 1999;116:625-32.
91. 91 Russell G, Williams DAJ, Weller P, et al. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995;75:423-8.
92. 92 Van der Molen T, Postma DS, Turner MO, et al. Effects of the long-acting beta-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1996;52:535-9.
93. 93 Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
94. 94 Taylor DR, Town GI, Herbison GP, et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998;53:744-52.
95. 95 Leblanc P, Knight A, Kreisman H, et al. A placebo-controlled, cross-over comparison of salmeterol and salbutamol in patients with asthma. Am J Respir Crit Care Med 1996;154:324-8.
96. 96 Pedersen B, Faurschou P, Madsden F, et al. Salmeterol treatment reduces the need for inhaled steroid in steroid-dependent asthmatics: a randomised, double-blind placebo-controlled parallel-group study. Eur Respir J 1996; 9:50s.
97. 97 Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336: 1391-6.
98. 98 Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta-agonist: effects on exacerbations and lung function. Thorax 1993;48:134-8.